Abstract. Colorectal cancer (CRC) is one of the most common and serious types of malignancy worldwide. The embryonic ectoderm development (EED) gene is important to maintain transcriptional repressive states of genes over successive cell generations. The present study aimed to investigate the association between EED methylation and CRC. A total of 111 CRC tissue samples, 111 paired para-tumor tissues and 20 colorectal normal tissues were obtained for EED methylation assay, which was performed using a quantitative methylation-specific polymerase chain reaction. The percentage of methylated reference was calculated to represent the DNA methylation level. A dual-luciferase reporter gene assay was used to detect the gene promoter activity of a EED fragment. The current results revealed a significant difference in the EED methylation levels among tumor, para-tumor and normal colorectal tissues (tumor vs. para-tumor vs. normal, 5.03±4.61 vs. 8.65±11.50 vs. 40.12±45.31; F=45.014; P<0.0001). The dual-luciferase reporter gene assay demonstrated that the transcriptional activity of recombinant pGL3-EED plasmid was significantly higher compared with that of the pGL3-Basic control vector (fold-change, 3.15; P=0.014), which suggests the EED fragment can promote gene expression. In conclusion, the present study demonstrated that EED hypomethylation may be an important factor associated with CRC.
Introduction
Colorectal cancer (CRC) is one of the most common and serious malignancies in the world, particularly in developed countries (1) . In England and Wales between 1991 and 1998, the 5-year survival rate of CRC in the initial stages was 60-95%, markedly decreasing to 35% in stages where lymph node metastases are detected (2) . The lifetime risk of CRC is ~5%, and almost 45% of patients succumb to CRC, despite treatment (1) . In China, although CRC is not the leading cause of cancer-associated mortality, the incidence and mortality rates of CRC have been increasing over the past 20 years, and they have been predicted to continue to increase if no effective intervention occurs (3) .
The initiation and progression of human cancer depends on both genetic alterations and epigenetic changes (4) . The carcinogenesis of CRC has been revealed to be involved in epigenetic alterations, including DNA methylation and histone modifications (5, 6) . Gene silencing caused by aberrant promoter methylation acts as one of the most significant epigenetic mechanisms (7) . In CRC, methylation alterations frequently occur in chromosomes 1, 5, 6, 8, 11, 13, 18, 19, 21 and 22 (8) . Differentially methylated DNA regions have been identified in both primary tumor tissues and blood samples (9) , and more recently in cell-free DNA (10) .
The embryonic ectoderm development (EED) gene, encodes a member of the Polycomb-group (PcG) family, which has been demonstrated to maintain the transcriptional repressive states of genes over successive cell generations (11) . PcG genes have been revealed to be highly mutated in a number of human diseases (12) . In addition, PcG proteins have been identified to be associated with cancer development (13) and proposed as potential targets for cancer therapeutic strategies (14) . EED has been identified to mediate the repression of gene activity through histone deacetylation (15) . EED hypermethylation has been detected in cholangiocarcinoma tumors (16 DNA methylation assay. DNA extraction and bisulfite conversion were performed as described previously (19) . Quantitative methylation-specific polymerase chain reaction (qMSP) was used to detect the methylation levels. qMSP was performed as described in our previous studies (20) (21) (22) . The percent of methylated reference (PMR) was used to represent gene methylation (23, 24) . The genomic position and function annotations of EED were obtained from the university of California Santa Cruz genome browser (GRCh37/hg19; http://genome.ucsc.edu/index. html). The primer sequences of EED were 5'-GAG GCG GAG GAA TAT GTT-3' for the forward primer and 5'-TCA CTA CTC AAC TTC TAC TTC T-3' for the reverse primer. The primer sequences of ACTB were 5'-TGG TGA TGG AGG AGG TTT AGT AAG T-3' for the forward primer and 5'-AAC CAA TAA AAC CTA CTC CTC CCT TAA-3' for the reverse primer. The current study used qMSP with internal negative and positive controls, and a reference gene control for the methylation assay of EED. China), were cultured as previously described (26) . The fragment of EED (-300 bp to +390 bp) was chemically synthesized according to the manufacturer's protocol (TransLipid HL Transfection Reagent; TransGen Biotech, Co., Ltd., Beijing, China) and digested with XhoI and KpnI (New England BioLabs, inc., ipswich, MA, uSA). The fragment was then purified by Cycle Pure kit (omega Bio-Tek, inc., Norcross, GA, uSA) and the target DNA fragment was cloned into a pGL3 vector (Promega Cooperation, Madison, WI, uSA) using DNA Ligation kit (Takara Bio, inc., otsu, Japan). The empty pGL3 basic vector was used as the negative control and the pGL3 promoter vector (both Promega Cooperation, Madison, WI, uSA) was used as the positive control, which contained an SV40 promoter upstream of the luciferase gene. The plasmid transfection and the detection of luciferase activity were performed as previously described (23, 27 
Results
In the present study, a total of 111 CRC tumor tissues, 111 paired para-tumor tissues and 20 colorectal normal tissues were obtained to investigate the role of EED promoter methylation in CRC.
Characteristics of the target sequence on the EED promoter region. The genomic region and target sequence of EED are presented in Fig. 1A . One CpG site was located in the primers of the tested fragment (hg19, chr11:85956259-85956348). The capillary electrophoresis result revealed a pMSP product with a length of 90 base pairs, which was expected, and Sanger sequencing demonstrated that the amplified fragment matched the target sequence (Fig. 1B) .
Baseline characteristics of the methylation levels among patients. Subsequently, no significant difference was identified between EED methylation levels and clinical characteristics, including sex, age, tumor location, tumor size, differentiation and lymph node metastasis (Table I) . However, when the PMR difference value between methylation levels of tumor and para-tumor samples was used to perform the χ 2 test, the only significant association of PMR difference with clinical characteristics was identified for tumor location (P=0.039; Table ii) . Notably, a significant difference of EED methylation levels among tumor, para-tumor and normal colorectal tissues was revealed (tumor vs. para-tumor vs. normal: 5.03±4.61 vs. 8.65±11.50 vs. 40.12±45.31; F=45.014; P<0.0001; Fig. 2) . Following Bonferroni's correction the results were as follows:
Tumor vs. para-tumor, P=0.237; tumor vs. normal tissue, P<0.0001; and para-tumor vs. normal tissue, P<0.0001 (Fig. 2) . Previous studies have demonstrated that bisulfite sequencing PCR and qMSP can yield similar conclusions (28, 29) . Bisulfite sequencing PCR is a reliable and accurate method; however, it is labor intensive and therefore only applicable for methylation in a limited number of samples. 
Diagnostic value of EED methylation.
A further estimation of the diagnostic value of EED methylation for CRC revealed an area under the curve (AuC) of 0.574 (95% CI, 0.498-0.650) with a sensitivity of 33.3% and a specificity of 89.2% between tumor and para-tumor tissues (median PMR, 4.54 vs. 4.90%; P=0.056; Fig. 3) . Furthermore, an AuC of 0.855 (95% CI, 0.729-0.981) with a sensitivity of 80% and a specificity of 89.2% was identified between tumor tissues and normal colorectal tissues (median PMR, 4.54 vs. 18.97%; P<0.0001; Fig. 3 ). In addition, an AuC of 0.787 (95% CI, 0.657-0.917) with a sensitivity of 65% and a specificity of 86.5% was revealed between para-tumor tissues and normal colorectal tissues (median PMR, 4.90 vs. 18.97%; P<0.0001; Fig. 3 ).
Characteristics of EED expression and methylation.
A dual-luciferase reporter gene assay was performed to evaluate whether the EED fragment (-300 bp to +390 bp) was able to regulate gene expression. The dual-luciferase assay demonstrated that the transcriptional activity of recombinant pGL3-EED plasmid was significantly higher compared with the pGL3-Basic control vector (pGL3-EED vs. pGL3-Basic vs. pGL3-Promoter: 2.05±0.19 vs. 0.65±0.02 vs. 30.27±0.26; F=16589.76; P<0.0001; pGL3-EED vs. pGL3-Basic: fold-change, 3.15; P=0.014; pGL3-EED vs. pGL3-Promoter: P<0.0001; pGL3-Basic vs. pGL3-Promoter: P<0.0001; Fig. 4) , which indicates that the EED fragment is able to promote gene expression.
Furthermore, EED mRNA expression and methylation data of patients with CRC were obtained from TCGA online database to investigate their correlation. Spearman correlation test revealed that EED mRNA expression level was inversely correlated with methylation (r=-0.248; P<0.0001; Fig. 5 ). In addition, a further analysis of GEO data (GSE32323) demonstrated that EED expression level in three CRC cell lines (COLO320, HT29 and RKO) was increased following 5'-AZA-deoxycytidine treatment (average fold-change, 1.44; Figure 2 . Comparisons of EED methylation levels among tumor tissues, paired para-tumor tissues and normal colorectal tissues. Analysis of variance was applied among tumor, para-tumor and normal samples. Data are presented as the mean ± standard deviation. P<0.05 was considered to indicate a statistically significant difference. EED, embryonic ectoderm development. Fig. 6 ). In summary, the present results indicate that EED hypomethylation is likely to upregulate EED expression and eventually increase the risk of CRC.
Discussion
In the current study, EED methylation levels were detected in 111 pairs of CRC tumor and para-tumor tissues from patients with CRC and 20 colorectal tissues from normal controls. The Receiver operating characteristic curves of EED methylation as a diagnostic marker for colorectal cancer. The AuC of EED methylation yielded a sensitivity of 33.3% and a specificity of 89.2% between tumor and para-tumor tissues, a sensitivity of 80% and a specificity of 89.2% between tumor tissues and normal colorectal tissues, and a sensitivity of 65% and a specificity of 86.5% between para-tumor tissues and normal colorectal tissues. P<0.05 was considered to indicate a statistically significant difference. AuC, area under the curve; EED, embryonic ectoderm development. Figure 6 . Expression value changes with and without 5-AZA treatment in COLO320, HT29 and RKO cell lines. The data were obtained from the Gene Expression Omnibus database (GSE32323) and expression was presented as a fold-change. The EED expression level was higher in three colorectal cell lines (COLO320, HT29 and RKO) following 5-AZA treatment. 5-AZA, 5'-AZA-deoxycytidine; EED, embryonic ectoderm development. results revealed that EED hypomethyation was significantly associated with the risk of CRC. In addition, the dual-luciferase reporter gene assay demonstrated that the EED fragment exhibited promoter activity. Further bioinformatics analyses revealed that EED methylation was inversely correlated with EED expression and demethylation treatment was identified to upregulate EED expression.
EED is a key component of the polycomb repressive complex 2 (PRC2) (30) , which can mediate epigenetic silencing of genes associated with worse survival of patients with colon cancer (31) . Higher expression of EED and two other PRC2 components has been demonstrated to contribute to the progression of CRC (17) .
Polymorphism of EED gene has been identified to be associated with the lymph node metastatic process of CRC (32) . In addition, EED expression has been demonstrated to be regulated by interleukin-22 and signal transducer and activator of transcription 3 (33) . EED mRNA levels are significantly higher in CRC tissues compared with non-cancerous tissues (17) . The dual-luciferase reporter gene assay performed in the current study demonstrated an enhanced transcriptional activity of the cloned EED fragment. Furthermore, data from TCGA and GEO databases suggested that EED methylation was associated with decreased expression levels of EED. This supports the hypothesis that EED hypomethylation may promote CRC via upregulation of EED expression. The present study identified that EED expression may be regulated by the methylation of its promoter, which may promote understanding of the role of EED in CRC.
Previous studies have revealed that DNA cytosine modifications serve an important role in cancer biology, and provide promising biomarkers for cancer diagnosis and prognosis evaluation (10, 34) . Several epigenetic biomarkers have been studied for the diagnosis of CRC, including SEPT9 (35), BMP3, NDRG4 (36) and hMLH1 (37) . The ROC curves generated in the current study demonstrated that EED hypomethylation is a good biomarker for the diagnosis of CR. Tumor vs. para-tumor revealed a sensitivity of 33.3% and a specificity of 89.2%. Tumor vs. normal tissue analysis demonstrated a sensitivity of 80% and a specificity of 89.2%. Finally, para-tumor vs. normal tissue revealed a sensitivity of 65% and a specificity of 86.5%.
However, there were a number of limitations of the present study. Firstly, the GEO analyses to investigate the effect of demethylation agent on EED expression involved data from only three cell lines. Furthermore, a comparison of EED mRNA expression level between 17 paired tumor and non-cancerous tissues from TCGA database yielded an insignificant result (4.45±0.58 vs. 4.32±0.50; P= 0.393), although this discrepancy may be due to different ethnic samples and a small sample size. Future studies are required to confirm the current findings and further address the functional roles of EED methylation in CRC. In conclusion, the present results demonstrated that EED hypomethylation might be an important risk factor associated with CRC.
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